Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trialJacqueline Palace, Carolina Mainella, Dean M. Wingerchuk et al.|Multiple Sclerosis and Related Disorders|2020Cited by 41
[Prevalence of neurocysticercosis in individuals affected by epilepsy].Guillermo Palacio, I Jiménez, Marta Jiménez et al.|PubMed|1997Cited by 5